Cargando…

Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors

[Image: see text] Many important physiological processes are mediated by alpha2A- and alpha2C-adrenergic receptors (α2Rs), a subtype of class A G protein-coupled receptors (GPCRs). However, α2R signaling is poorly understood, and there are few approved medications targeting these receptors. Drug dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragola, Nicholas R., Brems, Brittany M., Mukherjee, Munmun, Cui, Meng, Booth, Raymond G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628895/
https://www.ncbi.nlm.nih.gov/pubmed/37104867
http://dx.doi.org/10.1021/acschemneuro.3c00148
_version_ 1785131858149769216
author Fragola, Nicholas R.
Brems, Brittany M.
Mukherjee, Munmun
Cui, Meng
Booth, Raymond G.
author_facet Fragola, Nicholas R.
Brems, Brittany M.
Mukherjee, Munmun
Cui, Meng
Booth, Raymond G.
author_sort Fragola, Nicholas R.
collection PubMed
description [Image: see text] Many important physiological processes are mediated by alpha2A- and alpha2C-adrenergic receptors (α2Rs), a subtype of class A G protein-coupled receptors (GPCRs). However, α2R signaling is poorly understood, and there are few approved medications targeting these receptors. Drug discovery aimed at α2Rs is complicated by the high degree of binding pocket homology between α2AR and α2CR, which confounds ligand-mediated selective activation or inactivation of signaling associated with a particular subtype. Meanwhile, α2R signaling is complex and it is reported that activating α2AR is beneficial in many clinical contexts, while activating α2CR signaling may be detrimental to these positive effects. Here, we report on a novel 5-substituted-2-aminotetralin (5-SAT) chemotype that, depending on substitution, has diverse pharmacological activities at α2Rs. Certain lead 5-SAT analogues act as partial agonists at α2ARs, while functioning as inverse agonists at α2CRs, a novel pharmacological profile. Leads demonstrate high potency (e.g., EC(50) < 2 nM) at the α2AR and α2CRs regarding Gα(i)-mediated inhibition of adenylyl cyclase and production of cyclic adenosine monophosphate (cAMP). To help understand the molecular basis of 5-SAT α2R multifaceted functional activity, α2AR and α2CR molecular models were built from the crystal structures and 1 μs molecular dynamics (MD) simulations and molecular docking experiments were performed for a lead 5-SAT with α2AR agonist and α2CR inverse agonist activity, i.e., (2S)-5-(2′-fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine (FPT), in comparison to the FDA-approved (for opioid withdrawal symptoms) α2AR/α2CR agonist lofexidine. Results reveal several interactions between FPT and α2AR and α2CR amino acids that may impact the functional activity. The computational data in conjunction with experimental in vitro affinity and function results provide information to understand ligand stabilization of functionally distinct GPCR conformations regarding α2AR and α2CRs.
format Online
Article
Text
id pubmed-10628895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-106288952023-11-08 Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors Fragola, Nicholas R. Brems, Brittany M. Mukherjee, Munmun Cui, Meng Booth, Raymond G. ACS Chem Neurosci [Image: see text] Many important physiological processes are mediated by alpha2A- and alpha2C-adrenergic receptors (α2Rs), a subtype of class A G protein-coupled receptors (GPCRs). However, α2R signaling is poorly understood, and there are few approved medications targeting these receptors. Drug discovery aimed at α2Rs is complicated by the high degree of binding pocket homology between α2AR and α2CR, which confounds ligand-mediated selective activation or inactivation of signaling associated with a particular subtype. Meanwhile, α2R signaling is complex and it is reported that activating α2AR is beneficial in many clinical contexts, while activating α2CR signaling may be detrimental to these positive effects. Here, we report on a novel 5-substituted-2-aminotetralin (5-SAT) chemotype that, depending on substitution, has diverse pharmacological activities at α2Rs. Certain lead 5-SAT analogues act as partial agonists at α2ARs, while functioning as inverse agonists at α2CRs, a novel pharmacological profile. Leads demonstrate high potency (e.g., EC(50) < 2 nM) at the α2AR and α2CRs regarding Gα(i)-mediated inhibition of adenylyl cyclase and production of cyclic adenosine monophosphate (cAMP). To help understand the molecular basis of 5-SAT α2R multifaceted functional activity, α2AR and α2CR molecular models were built from the crystal structures and 1 μs molecular dynamics (MD) simulations and molecular docking experiments were performed for a lead 5-SAT with α2AR agonist and α2CR inverse agonist activity, i.e., (2S)-5-(2′-fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine (FPT), in comparison to the FDA-approved (for opioid withdrawal symptoms) α2AR/α2CR agonist lofexidine. Results reveal several interactions between FPT and α2AR and α2CR amino acids that may impact the functional activity. The computational data in conjunction with experimental in vitro affinity and function results provide information to understand ligand stabilization of functionally distinct GPCR conformations regarding α2AR and α2CRs. American Chemical Society 2023-04-27 /pmc/articles/PMC10628895/ /pubmed/37104867 http://dx.doi.org/10.1021/acschemneuro.3c00148 Text en © 2023 American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Fragola, Nicholas R.
Brems, Brittany M.
Mukherjee, Munmun
Cui, Meng
Booth, Raymond G.
Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors
title Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors
title_full Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors
title_fullStr Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors
title_full_unstemmed Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors
title_short Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors
title_sort conformationally selective 2-aminotetralin ligands targeting the alpha2a- and alpha2c-adrenergic receptors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628895/
https://www.ncbi.nlm.nih.gov/pubmed/37104867
http://dx.doi.org/10.1021/acschemneuro.3c00148
work_keys_str_mv AT fragolanicholasr conformationallyselective2aminotetralinligandstargetingthealpha2aandalpha2cadrenergicreceptors
AT bremsbrittanym conformationallyselective2aminotetralinligandstargetingthealpha2aandalpha2cadrenergicreceptors
AT mukherjeemunmun conformationallyselective2aminotetralinligandstargetingthealpha2aandalpha2cadrenergicreceptors
AT cuimeng conformationallyselective2aminotetralinligandstargetingthealpha2aandalpha2cadrenergicreceptors
AT boothraymondg conformationallyselective2aminotetralinligandstargetingthealpha2aandalpha2cadrenergicreceptors